SP-A preserves airway homeostasis during Mycoplasma pneumoniae infection in mice

Julie G Ledford1, Hisatsugu Goto, Erin N Potts

  • 1Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA.

Insights

Surfactant protein-A (SP-A) is crucial for lung defense against Mycoplasma pneumoniae (Mp) infection. Lacking SP-A exacerbates inflammation and lung dysfunction, highlighting SP-A's protective role.

Area of Science:

  • Pulmonary immunology
  • Host-pathogen interactions
  • Respiratory medicine

Background:

  • The lung's defense mechanisms maintain homeostasis against environmental irritants and pathogens.
  • Surfactant protein-A (SP-A) is a key component of pulmonary host defense, modulating inflammatory and infectious responses.
  • SP-A exhibits bacteriostatic effects on Mycoplasma pneumoniae (Mp) by binding to its surface.

Purpose of the Study:

  • To investigate the role of SP-A in acute pulmonary infection with Mycoplasma pneumoniae.
  • To assess the impact of SP-A deficiency on biologic and physiologic responses to Mp infection.

Main Methods:

  • Utilized SP-A deficient (SP-A(-/-)) mice and wild-type littermates for infection studies.
  • Administered Mycoplasma pneumoniae to induce acute pulmonary infection.
  • Pharmacologically inhibited TNF-alpha to evaluate its role in Mp-induced responses.

Main Results:

  • SP-A(-/-) mice exhibited significantly greater inflammation and cellular infiltration during Mp infection compared to wild-type mice.
  • Physiologic lung functions, including airway hyperresponsiveness and lung compliance, were more severely impaired in SP-A(-/-) mice.
  • Pharmacologic inhibition of TNF-alpha attenuated both biologic and physiologic changes induced by Mp infection.

Conclusions:

  • SP-A is essential for maintaining lung homeostasis and effective host defense against Mycoplasma pneumoniae.
  • SP-A limits inflammatory cell recruitment and curbs excessive TNF-alpha responses during Mp infection.
  • Targeting SP-A or TNF-alpha may offer therapeutic strategies for pulmonary infections.